Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
- Associated Therapies
- -
Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 98
- Registration Number
- NCT02177552
- Locations
- 🇩🇰
Finsen Center, Rigshospitalet, Copenhagen, Denmark
A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 401
- Registration Number
- NCT02132949
- Locations
- 🇵🇱
Wielkopolskie Centrum Onkologii; im. Marii Skłodowskiej-Curie, Poznan, Poland
🇵🇹Centro Clinico Champalimaud; Oncologia Medica, Lisboa, Portugal
🇺🇸Berkshire Medical Center, Pittsfield, Massachusetts, United States
A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
- Conditions
- Interventions
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 961
- Registration Number
- NCT02125344
- Locations
- 🇩🇪
NTC, Heidelberg, Baden-Württemberg, Germany
4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF
- Conditions
- Interventions
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2019-10-03
- Lead Sponsor
- West German Study Group
- Target Recruit Count
- 2011
- Registration Number
- NCT02115204
- Locations
- 🇩🇪
Ev. Hospital Bethesda, Moenchengladbach, Germany
Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2014-04-15
- Lead Sponsor
- Guangxi Medical University
- Target Recruit Count
- 100
- Registration Number
- NCT02115152
- Locations
- 🇨🇳
Breast Cancer Surgery Department of Guangxi Medical University Cancer Center, Nanning, Guangxi, China
Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2019-10-09
- Target Recruit Count
- 171
- Registration Number
- NCT02076594
- Locations
- 🇮🇹
Ospedale L. Sacco, Milano, MI, Italy
🇮🇹Osped. Di Circolo Serbelloni-Gorgonzola, Gorgonzola, MI, Italy
🇮🇹Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, BG, Italy
Study of Danggui Buxue Decoction in Preventing Neutropenia
- Conditions
- Interventions
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 50
- Registration Number
- NCT02005783
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 650
- Registration Number
- NCT01985724
- Locations
- 🇬🇷
"IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece
🇬🇷"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece
🇬🇷Air Forces Military Hospital of Athens, Athens, Greece
Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 34
- Registration Number
- NCT01985841
- Locations
- 🇬🇷
"IASO" General Hospital of Athens, Athens, Greece
🇬🇷"Metaxa's" Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology, Piraeus, Greece
🇬🇷University Hospital of Crete, Dep of Medical Oncology Heraklion, Greece, Heraklion, Greece
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
- First Posted Date
- 2013-10-21
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1846
- Registration Number
- NCT01966471
- Locations
- 🇨🇦
Princess Margaret Cancer Center, Toronto, Ontario, Canada
🇦🇺Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇯🇵Niigata Cancer Ctr Hospital; Breast Surgery, Niigata, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.